Lethal outcome of 5-fluorouracil infusion in a patient with a total DPD deficiency and a double DPYD and UTG1A1 gene mutation

被引：18

作者：

Mounier-Boutoille, Helene ^{[1
,2
]}

Boisdron-Celle, Michele ^{[3
]}

Cauchin, Estelle ^{[1
,2
]}

Galmiche, Jean-Paul ^{[1
,2
]}

Morel, Alain ^{[3
]}

Gamelin, Erick ^{[3
]}

Matysiak-Budnik, Tamara ^{[1
,2
]}

机构：

[1] CHU Nantes, IMAD, INSERM, CIC 04, F-44093 Nantes, France

[2] CHU Nantes, Hotel Dieu, Serv Hepatogastroenterol, F-44093 Nantes, France

[3] Ctr Rech Cancerol Angers, INSERM, CRLCC Paul Papin Angers, U892,Lab Oncopharmacol & Pharmacogenet, Nantes, France

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2010年 / 70卷 / 02期

关键词：

DIHYDROPYRIMIDINE DEHYDROGENASE GENE; IVS14+1G-GREATER-THAN-A MUTATION; TOXICITY; PREVALENCE; FLUOROPYRIMIDINES; IDENTIFICATION; POLYMORPHISMS; FLUOROURACIL; FREQUENCY; RELEVANCE;

D O I：

10.1111/j.1365-2125.2010.03686.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：280 / 283

页数：4

共 20 条

[1] 5-fluorouracil-related severe toxicity: A comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency [J].

Boisdron-Celle, M. ;

Remaud, G. ;

Traore, S. ;

Poirier, A. L. ;

Gamelin, L. ;

Morel, A. ;

Gamelin, E. .

CANCER LETTERS, 2007, 249 (02) :271-282

[2] Dihydropyrimidine dehydrogenase enzyme deficiency:: Clinical and genetic assessment of prevalence in Turkish cancer patients [J].

Çelik, I ;

Kars, A ;

Guc, D ;

Tekuzman, G ;

Ruacan, S .

CANCER INVESTIGATION, 2002, 20 (03) :333-339

[3]

Ezzeldin H, 2003, CLIN CANCER RES, V9, P3021

[4]

HEGGIE GD, 1987, CANCER RES, V47, P2203

[5] Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity [J].

Milano, G ;

Etienne, MC ;

Pierrefite, V ;

Barberi-Heyob, M ;

Deporte-Fety, R ;

Renée, N .

BRITISH JOURNAL OF CANCER, 1999, 79 (3-4) :627-630

[6] Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma [J].

Morel, A. ;

Boisdron-Celle, M. ;

Fey, L. ;

Laine-Cessac, P. ;

Gamelin, E. .

CLINICAL BIOCHEMISTRY, 2007, 40 (1-2) :11-17

[7] Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance [J].

Morel, Alain ;

Boisdron-Celle, Michele ;

Fey, Luc ;

Soulie, Patrick ;

Craipeau, Marie Claire ;

Traore, Sori ;

Gamelin, Erick .

MOLECULAR CANCER THERAPEUTICS, 2006, 5 (11) :2895-2904

[8] How may anticancer chemotherapy with fluorouracil be individualised? [J].

Ploylearmsaeng, Su-arpa ;

Fuhr, Uwe ;

Jetter, Alexander .

CLINICAL PHARMACOKINETICS, 2006, 45 (06) :567-592

[9]

Raida M, 2001, CLIN CANCER RES, V7, P2832

[10] An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice [J].

Remaud, G ;

Boisdron-Celle, M ;

Harneline, C ;

Morel, A ;

Gamelin, E .

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2005, 823 (02) :98-107

← 1 2 →